Epilepsy Surgery Market Research Report - Forecast till 2027

Epilepsy Surgery Market: Information by Procedure Type (Resective Surgery, Laser Interstitial Thermal Therapy (LITT),), by End User (Hospitals & Clinics, Specialty Centers) and by Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027

ID: MRFR/HC/9192-CR | September 2021 | Region: Global | 105 Pages         

Epilepsy Surgery Market

Epilepsy Surgery Market Is Estimated to Grow USD 1,402.32 Million With Healthy CAGR of 5.72% by 2027

Segmentation

By Procedure Type Resective Surgery Laser Interstitial Thermal Therapy (LITT)
By End User Hospitals & Clinics Specialty Centers)

Key Players

  • Stryker (US)
  • Zimmer Biomet Holdings Inc. (US)
  • Auris Health
  • Inc. (Hansen Medical Inc.) (US)
  • Intuitive Surgical (US)
  • Medtronic Plc (Mazor Robotics) (Ireland)
  • Cephalon Inc (US)
  • CMR Surgical (UK)
  • Natus Medical Incorporated (US)
  • Livanova Plc (UK)
  • Monteris Medical (US)

Drivers

  • Increasing prevalence of epilepsy and demand for surgical procedures
  • Rising number of cases of brain injuries due to road accidents
  • Advancement and adoption of robot-assisted surgery
Speak to Analyst Request a Free Sample

Epilepsy Surgery Market Outlook:

The epilepsy surgery market is expected to cross USD 1,402.32 million by 2027 at a CAGR of 5.72%.  


Market Overview:


Epilepsy surgery is a neurosurgical procedure that involvepilepsy surgery marketes treatment of the brain involved in seizures. The procedure is carried out to reduce or eliminate the possibility of seizures.


The growth of the epilepsy surgery market is attributed to the increasing prevalence of neurological disorders leading to extensive R&D on epilepsy treatment devices and increasing cases of brain injuries due to road accidents. Furthermore, advances in robot-assisted surgery and an increase in the geriatric population are likely to drive market expansion. However, risks associated with epilepsy surgeries may hamper the market growth.


COVID-19 Analysis:


The COVID-19 pandemic has disrupted the supply chain and interrupted the entire value chain of the epilepsy surgery market, from raw material procurement to manufacturing, packaging, and distribution. With several manufacturers having the required raw material and end-product stock, the impact does not seem high for a short duration. However, if the pandemic prolongs and trade restrictions are extended, the effect is expected to rise.


The most regular surgical procedures were advised to be postponed except the life-threatening situations. The patients suffering from drug-resistant epilepsy were one such category. According to a study from three tertiary care epilepsy hospitals from Spain and Italy, among the 5,700 patients with epilepsy, only 14 tested positive for the COVID-19 during August 2020. The COVID-19 pandemic has impacted the delivery of care to people with epilepsy (PWE) in multiple ways, including limitations on in-person contact and restrictions on neurophysiological procedures. To better study the effect of the pandemic on PWE, members of the American Epilepsy Society were surveyed between April 30 and June 14, 2020. About 17% of the respondents noted worsening seizure frequency, while none noted an improvement in seizures in PWE with COVID-19. In this survey, the most important barriers experienced by PWE were lack of access to healthcare services due to closure and restrictions on elective care. Medications shortages for epilepsy were noted by approximately 44% of respondents.


Market Dynamics:


Market Drivers



  • Increasing prevalence of epilepsy and demand for surgical procedures


According to the WHO's fact sheets 2019, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. Epilepsy is the fourth most common neurological disease after migraines, stroke, and Alzheimer's. According to the Centers for Disease Control and Prevention (CDC), an estimated 1.2% (3.4 million) of the US population had active epilepsy in 2015. A research article published in 2018 on Sage Open Medicine assessed adult epileptic patients at the University of Gondar Referral Hospital, Ethiopia. A total of 79 adverse events, including fatigue, and gastrointestinal disturbance, were reported due to medication. Anticonvulsants or antiepileptic drugs are a diverse group of pharmacological agents used in the treatment of epileptic seizures.



  • Rising number of cases of brain injuries due to road accidents


Any traumatic brain injury (TBI) or head trauma can cause epilepsy or a seizure disorder. Common causes include car accidents, construction site accidents, falls resulting from dangerous and unsafe premises, and unsafe worksites. Head trauma is one of the leading causes of epilepsy and seizure disorders. According to the Association for Safe International Road Travel 2020, approximately 1.35 million people die in road crashes each year, and on average, 3,700 people lose their lives every day on the roads. Ministry of Road Transport and Highways, India reported that with only 1% of the world's vehicles, India accounts for 11% of the global death in road accidents.The eighth leading cause of deaths worldwide road traffic injuries. According to the Epilepsy Foundation (US), traumatic brain injury (TBI) is the most common cause of symptomatic epilepsy among those aged between 15 and 24. More severehead injuries, such as penetration injuries and depressed skull fractures, are more likely to cause seizure disorder.



  • Advancement and adoption of robot-assisted surgery


The Increasing adoption of assistant robots for efficient and accurate surgical planning & navigation is strengthening the epilepsy surgery market. The patients prefer minimally invasive procedures owing to considerably lower complication rates, better patient outcomes, and a reduction in surgery time. Epilepsy surgery requires equipment such as stereoelectroencephalography (SEEG), biopsy, thermal ablation of seizure foci or tumors, deep brain stimulation (DBS), to remove the epilepsy disorders.Moreover, specialized stereotactic frames were employed prior to computer-guided robotic arms adapted from the automotive industry for neurosurgical use. SEEG involves neurologists and neurosurgeons collaborating to develop a basic plan guided by a noninvasive presurgical epilepsy workup. A typical montage of 10 electrodes may provide more than 150 recording sites. Robotic stereotactic assistance for neurosurgery has been infrequently reported in the pediatric population.


Market Restraints



  • Stringent government regulations and complications associated with surgery


Different regulatory paths for neurosurgical devices have resulted in different availabilities of these devices in different geographic regions. Important and challenging aspects of clinical trials for neurosurgical devices include the choice of control or comparison condition and patient heterogeneity. A research article published in 2019 in BioMed Central (Neurology aimed to explore the different patient pathways, referral, and surgical timeframes, and surgical and medical treatment options for refractory epilepsy patients referred to Tertiary Epilepsy Clinics in New South Wales, Australia.


Market Opportunities



  • Collaboration with research institutes for market entrants to access global markets


Emerging markets are anticipated to offer potential growth opportunities for global players operating in the market due to technological advancements, the growing elderly population prone to seizure disorders, and government initiatives in undertaking research studies focused on epilepsy surgery. For example, Researchers at the São Carlos School of Engineering at the University Of São Paulo, Brazil, are developing a robot to be used during surgeries performed on children who have epilepsy. The researchers imported a state-of-the-art articulated mechanical arm of approximately 1.6 meters and 45 kilos from Germany to create the new technology. Players in the epilepsy surgery market compete to provide superior quality services and well-regulated patient services.


Epilepsy Surgery Market Share (%), by Procedure Type, 2020
Epilepsy Surgery Market by Type 2020
Source: MRFR Analysis


Value Chain Analysis


The epilepsy surgery market is projected to exhibit significant growth over the forecast period, attributed to factors such as rapid technological advancements in the devices, better medical facilities, and an increasing patient pool in need of surgical treatment. The value chain analysis for the epilepsy surgery market comprises four major components, starting with the research & product development, followed by the manufacturing of the products, distribution, and end with marketing & sales.


High investments are required in R&D for the development of the product, which increases the R&D expenditure. In addition, the product designs are ready, and the manufacturing process of the product starts. Some of the product development processes employed in the production of components are sometimes outsourced. Distribution is a vital part of any industry. In this market, distribution consists of intermediaries, direct selling, and others. The major buyers of the products are hospitals, clinics, ambulatory surgical centers, and specialty centers.


Segment Overview


The epilepsy surgery market has been divided based on procedure type and end user.


By procedure type



  • Resective surgery


Resective surgery involves the removal of a small portion of the brain. The surgeon cuts out brain tissues in the area of the brain where seizures occur, usually the site of a tumor, brain injury, or malformation. It is the most common epilepsy surgery. Around 70% of people who have temporal lobe surgery find that the surgery stops their seizures; furthermore, 20% report a reduced frequency of seizures. Epilepsy surgery is indicated in 30% to 40% of patients with refractory seizure disorders despite being on one year of therapy with an adequate dosage of antiepileptic therapy.



  • Laser Interstitial Thermal Therapy (LITT)


LITT (Laser Interstitial Thermal Therapy) is a minimally invasive procedure used to treat drug-resistant epilepsy or seizures that do not respond to medicine. Some patients with focal seizures, which originate in a single area of the brain, may benefit from LITT. The LITT surgery generally takes around three to four hours. The emergence of MRI-guided LITT systems is used for ablating neurological soft tissue.



  • Others


Lesinectomy, multiple subpial transections, hemispherectomy and hemispherectomy, corpus callosotomy, stereotactic radiosurgery, and other procedures are options for surgical treatment of epilepsy. The application of medical devices such as neurostimulation device implantations is another treatment option for epilepsy.


By end user


On the basis of end user, the market is dividedinto hospitals & clinics, specialty centers, and others.The hospitals &clinicssegment accounts for the largest share and is anticipated to register a CAGR of 6.56% from 2021 to 2027.



  • Hospitals &clinics


Hospitals &clinics are dominating the epilepsy surgery market based on end user. This share is majorly attributed to the increasing number of patients getting diagnosed with epilepsy and undergoing surgical procedures for epilepsy. Since advanced and complete treatments are available in the hospital, patients usually prefer to get treated there. Clinics are also the medical care centers that provide care for epilepsy patients. Some countries with the maximum number of hospitals offering treatment for this disease are Europe, the Americas, and developing countries such as India, China, and Russia.



  • Specialty centers


Specialized epilepsy centers provide routine care to individuals with seizures or epilepsy and specialize in providing comprehensive diagnostic and treatment services to individuals with uncontrolled seizures. The epilepsy center offers comprehensive treatment to patients of all ages. Treatment options at specialty centers to eliminate seizures or reduce the frequency and intensity of seizures in children and adults include medications, vagus nerve stimulation, and the ketogenic diet.



  • Others


The services such as electroencephalogram, a medical test used to measure the electrical activity of the brain, are conducted at diagnostic centers and neurology centers to assess the severity of seizures. Neurologists, neurosurgeons, radiologists, neuropsychologists, and other healthcare professionals help patients with surgical procedures.


Epilepsy Surgery Market Share (%), by Region, 2020
Epilepsy Surgery Market by Region 2020
Source: MRFR Analysis


Regional Analysis


The epilepsy surgery market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.



  • Americas:


The Americas dominated the epilepsy surgery market owing to various factors, such as the availability of well-established healthcare facilities, the high prevalence of neurological disorders, and the increasing incidence of epilepsy. North America is divided into the US and Canada. It is estimated that aproximately 150,000 Americans are diagnosed with Central Nervous System (CNS) disorder that causes seizures and is the fourth most common neurological disease. It is also found that the incidence rate is highest in young children under the age of 2 and adults aged 65 or older. Epilepsy cases are increasing in the Americas. In Canada, about 300,000 Canadians are affected by seizure disorder, and each year, one in 2,000 people is diagnosed with epilepsy. Neurological disorders are also among the leading causes of disability in the Canadian population.



  • Europe:


With increasing investment in research & development, the production of successful epilepsy medications, and a high prevalence of epilepsy, Europe has also evolved as a prominent market for epilepsy surgery. The region has considerable growth potential that would help with the expansion of the epilepsy surgery market in the coming years. According to the 2020 EU Industrial Research & Development Scoreboard, companies in the European Union have increased their investment in research & development. In 2019, European companies invested 5.6% more in R&D, compared to 4.7% in 2018. The production of successful medications to cure epilepsy in the region is increasing.



  • Asia-Pacific:


The Asia-Pacific region offers lucrative opportunities for players in the epilepsy surgery market, owing to the presence of a large geriatric population, governmental initiatives to improve the healthcare sector, an increase in research & development activities, and an increase in epilepsy incidence in the region. The prevalence of epilepsy in the elderly population is very high. It is estimated that the prevalence of epilepsy is 10.8 in 1,000. According to WHO, the population of the South-East Asia region is aging rapidly, and the proportion of people aged 60 or above was 9.7% in 2017. It is also estimated that the geriatric population will increase to 13.7% and 20.3% by 2030 and by 2050, respectively.



  • Middle East & Africa:


The Middle East &Africa epilepsy surgery market is segmented into major regions, namely the Middle East, Africa, and Latin America. Factors such as the increasing incidence of epilepsy, the rise in the geriatric population, and the increasing disposable income of people in the region are driving the epilepsy surgery market. Epilepsy affects approximately 10 million people on the African continent, according to WHO. The incidence of epilepsy is high in children and the aging population. According to WHO, the population of elderly people in sub-Saharan Africa is projected to reach 67 million by 2025 and 163 million by 2050.


Competitive Landscape


The epilepsy surgery market is distinguished by the presence of numerous global, regional, and local players catering to the rising prevalence of neurological disorders, which has resulted in extensive research & development of epilepsy treatment devices, rising cases of brain injuries due to car accidents, and advancements in robot-assisted surgery. The increasing prevalence of epilepsy and the growing geriatric population around the globe are making the epilepsy surgery market more lucrative. The major players have adopted a strategy of obtaining regulatory approvals from government agencies for their drugs and devices and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in February 2019, Zimmer Biomet received US Food and Drug Administration (FDA) clearance for the ROSA One Brain Application, a robotic surgical navigation and positioning system for use in neurosurgical procedures. In February 2020, (US), which develops and distributes clinical video management and analytics platform for multiple surgical disciplines.


The business model developed by manufacturers in the global epilepsy surgery market includes manufacturing epilepsy surgery devices and systems locally to minimize operational costs. Mergers and collaborations were also observed to expand the company's product portfolio, as well as the introduction of new products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers of epilepsy surgery devices and systems are focusing on developing products with advanced technologies. Moreover, the market players are involved in promotional activities and marketing campaigns to promote their products. It is also projected that improving healthcare infrastructure in emerging regions and the rising target patient population will boost the market growth for epilepsy surgery in the upcoming future.


List of Key Companies Covered in this report:



  • Stryker (US)

  • Zimmer Biomet Holdings Inc. (US)

  • Auris Health, Inc. (Hansen Medical, Inc.) (US)

  • Intuitive Surgical (US)

  • Medtronic Plc (Mazor Robotics) (Ireland)

  • Cephalon, Inc. (US)

  • CMR Surgical (UK)

  • Natus Medical Incorporated (US)

  • Livanova Plc (UK)

  • Monteris Medical (US)


Recent Developments



  • In September 2020, CMR Surgical (UK) launched its Versius Surgical Robotic System at Clinique du Parc Hospital in Saint-Etienne, France. France is Europe’s largest robotics market and the third-largest worldwide.

  • In July 2020, Monteris Medical (US) received FDA clearance for NeuroBlate Fusion-S Software. NeuroBlate Fusion-S Software provides unprecedented visualization for neurosurgeons to ablate brain tissue, including tumors and epileptic foci.

  • In February 2020, Intuitive Surgical (US) acquired Orpheus Medical to develop and distribute clinical video management and analytics platforms for multiple surgical disciplines. This acquisition helps Intuitive Surgical to grow an integrated informatics platform.

  • In February 2019, Zimmer Biomet (US) received US Food and Drug Administration (FDA) clearance for the ROSA One Brain Application, a robotic surgical navigation and positioning system for use in neurosurgical procedures.

  • In February 2019, Medtronic (Ireland) launched its Deep Brain Stimulation system intended for medicallyrefractory epilepsy in the US. The DBS provides an important surgical treatment option for patients who suffer from epilepsy and do not respond to medication.


Report Overview:


The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


Epilepsy Surgery Market, by Procedure Type



  • Resective Surgery

  • Laser Interstitial Thermal Therapy (LITT)

  • Others


Epilepsy Surgery Market, by End User



  • Hospitals & Clinics

  • Specialty Centers

  • Others


Epilepsy Surgery Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

      • Germany

      • France

      • UK

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa





Report Scope:

Report Attribute/Metric Details
  Market Size   2027: USD 1,402.32Million
  CAGR   5.72%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2017 & 2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Procedure Type, End User, and Region
  Geographies Covered   Americas, Europe, Asia-Pacific, Middle East & Africa
  Key Vendors   • Stryker (US) • Zimmer Biomet Holdings Inc. (US) • Auris Health, Inc. (Hansen Medical, Inc.) (US) • Intuitive Surgical (US) • Medtronic Plc (Mazor Robotics) (Ireland) • Cephalon, Inc. (US) • CMR Surgical (UK) • Natus Medical Incorporated (US) • Livanova Plc (UK) • Monteris Medical (US)
  Key Market Opportunities   • Collaboration with research institutes for market entrants to access global markets
  Key Market Drivers   • Increasing prevalence of epilepsy and demand for surgical procedures • Rising number of cases of brain injuries due to road accidents • Advancement and adoption of robot-assisted surgery


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The epilepsy surgery market is expected to cross USD 1,402.32 million by 2027 at a CAGR of 5.72%.

Stryker(US),Zimmer Biomet Holdings Inc.(US),Auris Health, Inc. (Hansen Medical, Inc.) (US), Intuitive Surgical (US),Medtronic Plc (Mazor Robotics) (Ireland), Cephalon, Inc. (US), CMR Surgical(UK), Natus Medical Incorporated(US), Livanova Plc (UK), and Monteris Medical(US) are the key players in the market of epilepsy surgery

North America is predicted to lead the market of epilepsy surgery

Increasing prevalence of epilepsy and demand for surgical procedures and Rising number of cases of brain injuries due to road accidents are the major market driver of epilepsy surgery

Stringent government regulations and complications associated with surgery may limit the market growth of epilepsy surgery